Centessa Pharmaceuticals — Technical Presentation (February 2024)
14 slides from Centessa Pharmaceuticals's technical presentation, Feb 9, 2024
Slide 1: SerpinPC in persons with severe haemophilia: updated results from a first-in-human study
SerpinPC in persons with severe haemophilia (PwH): updated results from a multicentre multi-part, first-in-human study T Baglin*, A Koch, I Mocanu+, L Makhaldiani$, J Huntington* *Centessa Pharmaceuticals plc, 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT, Simbec-Orion Clinical Pha
Slide 2: Disclosures for Trevor Baglin
Disclosures for Trevor Baglin Employee Centessa Pharmaceuticals Shareholder Centessa Pharmaceuticals Grant / Research Support No relevant conflicts of interest to declare Consultant No relevant conflicts of interest to declare Paid Instructor No relevant conflicts of interest to declare Speaker bure
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be consid
Slide 4: SerpinPC inhibits circulating activated protein C (APC)
4 SerpinPC Inhibits circulating activated protein C (APC) P ro th ro m b in as e SerpinPC: a subcutaneously administered biologic inhibitor of APC
Slide 5: AP-0101 study design: adaptive first-in-human study of SerpinPC
AP-0101 study design: adaptive first-in-human study to investigate the safety, tolerability, efficacy and PK of SerpinPC 5 Part 1b SAD PwH (n=12) Up to 0.03 mpk 0.1 to 1.2 mpk Part 1a SAD HV (n=15) 1.2 mpk Q2W Part 2 MAD PwH (n=23) Part 3 flat dose (n=22) Part 4 1.2 mpk Q2W (n=21) Week 1 to 24 Week
Slide 6: AP-0101 Part 5: demographics, baseline characteristics and early terminations
AP-0101 Part 5: demographics, baseline characteristics and early terminations 6 Patient Characteristics Value Number of subjects (Hemophilia A / B) 20 (16 / 4) Age in years, median (min to max) 40 (21 to 56) Weight kg (min to max) 74 (54 to 91) Prospective ABR, median (min to max) 35.6 (23 to 53) %
Slide 7: AP-0101 Part 5: No observation of treatment-related adverse events
AP-0101 Part 5: No observation of treatment-related adverse events 7 Treatment Emergent Adverse Events (TEAEs) Number of subjects (%) n=20 All TEAEs (total 41 events) 16 (80%) Related to SerpinPC 0 Leading to discontinuation 1 (5%) Leading to death 0 AEs of special interest 0 Serious adverse events
Slide 8: AP-0101 Part 5: Reduction in Annualized Bleed Rate (ABR) & Target Joints
AP-0101 Part 5: Reduction in Annualized Bleed Rate (ABR) & Target Joints 8 Target Joints Baseline (n=20) Part 5 (n=20) Change (%) Target joints per patient (median) 3 0 -100% Total number of target joints in cohort 53 3 -94% Annualized Bleed Rate (ABR) Baseline (n=20) Part 5 (n=20) Change* (%) All b
Slide 9: 96% median reduction in annualized bleeding rates at 1.2 mpk Q2W
96% median reduction in annualized bleeding rates at 1.2 mpk Q2W after continuous treatment with SerpinPC 9 All Bleed ABR (n=20) • Median all bleed ABR of 1.0 • 96% median reduction from baseline in all bleed ABR • Only 2 subjects with target joints at end of Part 5 vs. all 20 patients with target j
Slide 10: No unexplained, sustained elevations of D-dimer over 148 weeks of treatment
0 100 200 300 400 500 600 700 0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114 120 126 132 138 144 150 No observations of unexplained, sustained elevations of D-dimer values over 148-weeks of treatment 10 Mean D-dimer1 (ng/ml) Part 3 (60 mg flat Q4W) n=23 Parts 4 & 5 (1.2 mpk Q2W) n=21,2
Slide 11: Pharmacokinetic parameters measured in Part 5
Pharmacokinetic parameters measured in Part 5 Parameter Mean value (std. dev.) Tmax (n=20) 74 hr (28) t1/2 (n=17) 99 hr (10) Cmax (n=20) 3184 ng/ml (1122) AUC0-t (n=19) 564 hr*mg/ml (148) AUC0-inf (n=17) 673 hr*mg/ml (21)
Slide 12: Consistent Ctrough with no evidence of accumulation (Parts 3, 4, 5)
1 10 100 1,000 10,000 24 40 56 72 88 108 124 140 Consistent Ctrough with no evidence of accumulation (Parts 3, 4, 5) 12 Part 3 (60 mg flat Q4W) Part 4 (1.2 mpk Q2W) ~3-fold increase in dose intensity Part 5 (1.2 mpk Q2W) Ctrough (ng/ml) Time on therapy (weeks)
Slide 13: Transient ADA response observed in Part 5
• In Part 5, 1 transient ADA response observed out of 20 subjects – Subject had a single instance of an ADA at the limit of detection (1:100 dilution). Same sample was negative in the neutralizing anti-drug antibody test – Subject had an ABR of 0.99 in Part 5 – Subject had an average Ctrough of 619
Slide 14: Summary
Summary 14 • SerpinPC was shown to have a safe and well tolerated profile after repeat dose exposure for 2.8 years – No observations of SerpinPC-related AE’s in Parts 2 through 5, except for 1 resolved, moderate injection site reaction in a subject with a pre- existing skin condition – No observatio
Centessa Pharmaceuticals — Technical Presentation (February 2024) on 6ix